Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials
Journal of the American College of Cardiology | 2 Aug 2014
SM Boekholdt, GK Hovingh, S Mora, BJ Arsenault, P Amarenco, TR Pedersen, JC LaRosa, DD Waters, DA DeMicco, RJ Simes, AC Keech, D Colquhoun, GA Hitman, DJ Betteridge, MB Clearfield, JR Downs, HM Colhoun, AM Gotto, PM Ridker, SM Grundy and JJ Kastelein
Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the consequence of this variability for cardiovascular disease risk is not well-documented.
* Data courtesy of Altmetric.com